We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Symbicort

News List

FDA Grants Tentative Approval to Generic Version of Symbicort contractpharma
March 10, 2021
Product is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD).
US court rules in favour of AstraZeneca in Symbicort patent litigation pharmaceutical-technology
March 04, 2021
A US district court for the Northern District of West Virginia has decided in favour of AstraZeneca in a patent litigation lawsuit against Mylan Pharmaceuticals, which is now part of Viatris, and Kindeva Drug Delivery.
New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever worldpharmanews
May 24, 2019
New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.
AZ Symbicort reduces rate of asthma attacks pharmatimes
May 20, 2019
AstraZeneca’s Novel START trial for its Symbicort Turbuhaler (budesonide/formoterol) demonstrated a reduction in the rate of asthma attacks in patients with mild asthma, compared to common therapies.